Skip to main content
SpringerLink
Log in

Potentially Malignant Disorders of the Oral Cavity

  • Chapter
Book cover Controversies in Oral Cancer

Part of the book series: Head and Neck Cancer Clinics ((HNCC))

  • 444 Accesses

Abstract

The term ‘potentially malignant disorder’ (PMD) of the oral cavity was created by a working group of the WHO Collaborating Centre for Oral Pathology and Precancer. It is currently used to describe ‘white plaques of questionable risk, having excluded other known diseases and diseases that carry no increased risk for cancer’ [1]. Not all lesions under the umbrella of PMD transform into cancer, but they are still included as they belong to a morphological group that has an increased potential for malignant transformation [1, 2]. Several clinical entities can be classified as a PMD, with the most common being leukoplakia, erythroplakia, lichen planus, oral submucous fibrosis, palatal lesions in reverse smokers, actinic keratosis and hereditary disorders with increased risk [1]. This chapter will examine oral leukoplakia, oral lichen planus (OLP), erythroplakia and oral submucous fibrosis; the clinical presentation, prevalence and risk factors, histology, molecular genetics, risk of malignant transformation and treatment will be discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Warnakulasuriya S, Johnson NW, van der Waal I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med 2007;36:575–80.

    Article  CAS  PubMed  Google Scholar 

  2. van der Waal I. Potentially malignant disorders of the oral and oropharyngeal mucosa: Terminology, classification and present concepts of management. Oral Oncol 2009;45:317–23.

    Article  PubMed  Google Scholar 

  3. van der Waal I. Potentially malignant disorders of the oral and oropharyngeal mucosa: Present concepts of management. Oral Oncol 2010;46:423–5.

    Article  PubMed  Google Scholar 

  4. Ribeiro AS, Salles PR, da Silva TA, et al. A review of the non-surgical treatment of oral leukoplakia. Int J Dent 2010;2010:186018.

    Article  PubMed Central  PubMed  Google Scholar 

  5. Roed-Petersen B. Effect on oral leukoplakia of reducing or ceasing tobacco smoking. Acta Derm Venereol 1982;62:164–7.

    CAS  PubMed  Google Scholar 

  6. Napier SS, Speight PM. Natural history of potentially malignant oral lesions and conditions: An overview of the literature. J Oral Pathol Med 2008;37:1–10.

    Article  PubMed  Google Scholar 

  7. Hashibe M, Jacob BJ, Thomas G, et al. Socioeconomic status, lifestyle factors and oral premalignant lesions. Oral Oncol 2003;39:664–71.

    Article  CAS  PubMed  Google Scholar 

  8. Dietrich T, Reichart PA, Scheifele C. Clinical risk factors of oral leukoplakia in a representative sample of the US population. Oral Oncol 2004;40:158–63.

    Article  PubMed  Google Scholar 

  9. Bagan JV, Jimenez Y, Murillo J, et al. Lack of association between proliferative verrucous leukoplakia and human papillomavirus infection. J Oral Maxillofac Surg 2007;65:46–9.

    Article  PubMed  Google Scholar 

  10. Eugene N. SJ (ed). Cancer of the head and neck. 3rd ed. Philadelphia: WWB, Saunders; 1996.

    Google Scholar 

  11. Kujan O, Khattab A, Oliver RJ, et al. Why oral histopathology suffers inter-observer variability on grading oral epithelial dysplasia: An attempt to understand the sources of variation. Oral Oncol 2007;43:224–31.

    Article  PubMed  Google Scholar 

  12. Holmstrup P, Vedtofte P, Reibel J, et al. Long-term treatment outcome of oral premalignant lesions. Oral Oncol 2006;42:461–74.

    Article  CAS  PubMed  Google Scholar 

  13. Gupta PC, Mehta FS, Daftary DK, et al. Incidence rates of oral cancer and natural history of oral precancerous lesions in a 10-year follow-up study of Indian villagers. Community Dent Oral Epidemiol 1980;8:283–333.

    Article  CAS  PubMed  Google Scholar 

  14. Lind PO. Malignant transformation in oral leukoplakia. Scand J Dent Res 1987;95:449–55.

    CAS  PubMed  Google Scholar 

  15. Petti S. Pooled estimate of world leukoplakia prevalence: A systematic review. Oral Oncol 2003;39:770–80.

    Article  PubMed  Google Scholar 

  16. Bilodeau E, Alawi F, Costello BJ, et al. Molecular diagnostics for head and neck pathology. Oral Maxillofac Surg Clin North Am 2010;22:183–94.

    Article  PubMed  Google Scholar 

  17. Mithani SK, Mydlarz WK, Grumbine FL, et al. Molecular genetics of premalignant oral lesions. Oral Dis 2007;13:126–33.

    Article  CAS  PubMed  Google Scholar 

  18. Rosin MP, Cheng X, Poh C, et al. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res 2000;6:357–62.

    CAS  PubMed  Google Scholar 

  19. Partridge M, Emilion G, Pateromichelakis S, et al. Allelic imbalance at chromosomal loci implicated in the pathogenesis of oral precancer, cumulative loss and its relationship with progression to cancer. Oral Oncol 1998;34:77–83.

    Article  CAS  PubMed  Google Scholar 

  20. Lee JS, Kim SY, Hong WK, et al. Detection of chromosomal polysomy in oral leukoplakia, a premalignant lesion. J Natl Cancer Inst 1993;85:1951–4.

    Article  CAS  PubMed  Google Scholar 

  21. Fujimoto R, Kamata N, Yokoyama K, et al. Expression of telomerase components in oral keratinocytes and squamous cell carcinomas. Oral Oncol 2001;37:132–40.

    Article  CAS  PubMed  Google Scholar 

  22. Kovesi G, Szende B. Changes in apoptosis and mitotic index, p53 and Ki67 expression in various types of oral leukoplakia. Oncology 2003;65:331–6.

    Article  PubMed  CAS  Google Scholar 

  23. Thomson PJ, Hamadah O. Cancerisation within the oral cavity: The use of ‘field mapping biopsies’ in clinical management. Oral Oncol 2007;43:20–6.

    Article  CAS  PubMed  Google Scholar 

  24. Schepman KP, Bezemer PD, van der Meij EH, et al. Tobacco usage in relation to the anatomical site of oral leukoplakia. Oral Dis 2001;7:25–7.

    Article  CAS  PubMed  Google Scholar 

  25. Lodi G, Porter S. Management of potentially malignant disorders: Evidence and critique. J Oral Pathol Med 2008;37:63–9.

    Article  PubMed  Google Scholar 

  26. Sako K, Marchetta FC, Hayes RL. Cryotherapy of intraoral leukoplakia. Am J Surg 1972;124:482–4.

    Article  CAS  PubMed  Google Scholar 

  27. Meltzer C. Surgical management of oral and mucosal dysplasias: The case for laser excision. J Oral Maxillofac Surg 2007;65:293–5.

    Article  PubMed  Google Scholar 

  28. Lodi G, Sardella A, Bez C, et al. Interventions for treating oral leukoplakia. Cochrane Database Syst Rev 2006;4:CD001829.

    PubMed  Google Scholar 

  29. Stich HF, Hornby AP, Mathew B, et al. Response of oral leukoplakias to the administration of vitamin A. Cancer Lett 1988;40:93–101.

    Article  CAS  PubMed  Google Scholar 

  30. Sankaranarayanan R, Mathew B, Varghese C, et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: An assessment. Oral Oncol 1997;33:231–6.

    Article  CAS  PubMed  Google Scholar 

  31. Piattelli A, Fioroni M, Santinelli A, et al. Bcl-2 expression and apoptotic bodies in 13-cis-retinoic acid (isotretinoin)-topically treated oral leukoplakia: A pilot study. Oral Oncol 1999;35:314–20.

    Article  CAS  PubMed  Google Scholar 

  32. Hong WK, Endicott J, Itri LM, et al. 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986;315:1501–5.

    Article  CAS  PubMed  Google Scholar 

  33. Gaeta GM, Gombos F, Femiano F, et al. Acitretin and treatment of the oral leucoplakias. A model to have an active molecules release. J Eur Acad Dermatol Venereol 2000;14:473–8.

    Article  CAS  PubMed  Google Scholar 

  34. Fan KF, Hopper C, Speight PM, et al. Photodynamic therapy using 5-aminolevulinic acid for premalignant and malignant lesions of the oral cavity. Cancer 1996;78:1374–83.

    Article  CAS  PubMed  Google Scholar 

  35. Chen HM, Yu CH, Tu PC, et al. Successful treatment of oral verrucous hyperplasia and oral leukoplakia with topical 5-aminolevulinic acid-mediated photodynamic therapy. Lasers Surg Med 2005;37:114–22.

    Article  PubMed  Google Scholar 

  36. Sieron A, Adamek M, Kawczyk-Krupka A, et al. Photodynamic therapy (PDT) using topically applied delta-aminolevulinic acid (ALA) for the treatment of oral leukoplakia. J Oral Pathol Med 2003;32:330–6.

    Article  CAS  PubMed  Google Scholar 

  37. Kubler A, Haase T, Rheinwald M, et al. Treatment of oral leukoplakia by topical application of 5-aminolevulinic acid. Int J Oral Maxillofac Surg 1998;27:466–9.

    Article  CAS  PubMed  Google Scholar 

  38. Bouquot JE. Common oral lesions found during a mass screening examination. J Am Dent Assoc 1986;112:50–7.

    Article  CAS  PubMed  Google Scholar 

  39. Scully C, Beyli M, Ferreiro MC, et al. Update on oral lichen planus: Etiopathogenesis and management. Crit Rev Oral Biol Med 1998;9:86–122.

    Article  CAS  PubMed  Google Scholar 

  40. Markopoulos A, Kayavis I, Paleologoy A, et al. Oral lichen planus. A clinical study of 228 cases. Hell Stomatol Chron 1989;33:107–11.

    CAS  PubMed  Google Scholar 

  41. Lodi G, Scully C, Carrozzo M, et al. Current controversies in oral lichen planus: Report of an international consensus meeting. Part 1. Viral infections and etiopathogenesis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005;100:40–51.

    Article  PubMed  Google Scholar 

  42. Scully C, Carrozzo M. Oral mucosal disease: Lichen planus. Br J Oral Maxillofac Surg 2008;46:15–21.

    Article  PubMed  Google Scholar 

  43. Epstein JB, Wan LS, Gorsky M, et al. Oral lichen planus: Progress in understanding its malignant potential and the implications for clinical management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003;96:32–7.

    Article  PubMed  Google Scholar 

  44. Silverman S Jr, Gorsky M, Lozada-Nur F. A prospective follow-up study of 570 patients with oral lichen planus: Persistence, remission, and malignant association. Oral Surg Oral Med Oral Pathol 1985;60:30–4.

    Article  PubMed  Google Scholar 

  45. Gorsky M, Raviv M, Moskona D, et al. Clinical characteristics and treatment of patients with oral lichen planus in Israel. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996;82:644–9.

    Article  CAS  PubMed  Google Scholar 

  46. Kilpi AM. Activation marker analysis of mononuclear cell infiltrates of oral lichen planus in situ. Scand J Dent Res 1987;95:174–80.

    CAS  PubMed  Google Scholar 

  47. Jungell P, Konttinen YT, Nortamo P, et al. Immunoelectron microscopic study of distribution of T-cell subsets in oral lichen planus. Scand J Dent Res 1989;97:361–7.

    CAS  PubMed  Google Scholar 

  48. Santoro A, Majorana A, Bardellini E, et al. NF-kappaB expression in oral and cutaneous lichen planus. J Pathol 2003;201:466–72.

    Article  CAS  PubMed  Google Scholar 

  49. Karatsaidis A, Schreurs O, Axell T, et al. Inhibition of the transforming growth factor-beta/Smad signaling pathway in the epithelium of oral lichen. J Invest Dermatol 2003;121:1283–90.

    Article  CAS  PubMed  Google Scholar 

  50. Farhi D, Dupin N. Pathophysiology, etiologic factors, and clinical management of oral lichen planus, part I: Facts and controversies. Clin Dermatol 2010;28:100–8.

    Article  PubMed  Google Scholar 

  51. Lodi G, Scully C, Carrozzo M, et al. Current controversies in oral lichen planus: Report of an international consensus meeting. Part 2. Clinical management and malignant transformation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005;100:164–78.

    Article  PubMed  Google Scholar 

  52. Potts AJ, Hamburger J, Scully C. The medication of patients with oral lichen planus and the association of nonsteroidal anti-inflammatory drugs with erosive lesions. Oral Surg Oral Med Oral Pathol 1987;64:541–3.

    Article  CAS  PubMed  Google Scholar 

  53. Firth NA, Reade PC. Angiotensin-converting enzyme inhibitors implicated in oral mucosal lichenoid reactions. Oral Surg Oral Med Oral Pathol 1989;67:41–4.

    Article  CAS  PubMed  Google Scholar 

  54. Robertson WD, Wray D. Ingestion of medication among patients with oral keratoses including lichen planus. Oral Surg Oral Med Oral Pathol 1992;74:183–5.

    Article  CAS  PubMed  Google Scholar 

  55. Smart ER, Macleod RI, Lawrence CM. Resolution of lichen planus following removal of amalgam restorations in patients with proven allergy to mercury salts: A pilot study. Br Dent J 1995;178:108–12.

    Article  CAS  PubMed  Google Scholar 

  56. Laeijendecker R, van Joost T. Oral manifestations of gold allergy. J Am Acad Dermatol 1994;30:205–9.

    Article  CAS  PubMed  Google Scholar 

  57. Rojo-Moreno JL, Bagan JV, Rojo-Moreno J, et al. Psychologic factors and oral lichen planus. A psychometric evaluation of 100 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998;86:687–91.

    Article  CAS  PubMed  Google Scholar 

  58. McCartan BE. Psychological factors associated with oral lichen planus. J Oral Pathol Med 1995;24:273–5.

    Article  CAS  PubMed  Google Scholar 

  59. Rebora A. Lichen planus and the liver. Lancet 1981;2:805–6.

    Article  CAS  PubMed  Google Scholar 

  60. Lodi G, Giuliani M, Majorana A, et al. Lichen planus and hepatitis C virus: A multicentre study of patients with oral lesions and a systematic review. Br J Dermatol 2004;151:1172–81.

    Article  CAS  PubMed  Google Scholar 

  61. Grote M, Reichart PA, Berg T, et al. Hepatitis C virus (HCV) infection and oral lichen planus. J Hepatol 1998;29:1034–5.

    Article  CAS  PubMed  Google Scholar 

  62. Henderson L, Muir M, Mills PR, et al. Oral health of patients with hepatitis C virus infection: A pilot study. Oral Dis 2001;7:271–5.

    Article  CAS  PubMed  Google Scholar 

  63. Lodi G, Olsen I, Piattelli A, et al. Antibodies to epithelial components in oral lichen planus (OLP) associated with hepatitis C virus (HCV) infection. J Oral Pathol Med 1997;26:36–9.

    Article  CAS  PubMed  Google Scholar 

  64. Arrieta JJ, Rodriguez-Inigo E, Casqueiro M, et al. Detection of hepatitis C virus replication by in situ hybridization in epithelial cells of anti-hepatitis C virus-positive patients with and without oral lichen planus. Hepatology 2000;32:97–103.

    Google Scholar 

  65. Bigby M. The relationship between lichen planus and hepatitis C clarified. Arch Dermatol 2009;145:1048–50.

    Article  PubMed  Google Scholar 

  66. Plemons JM, Rees TD, Zachariah NY. Absorption of a topical steroid and evaluation of adrenal suppression in patients with erosive lichen planus. Oral Surg Oral Med Oral Pathol 1990;69:688–93.

    Article  CAS  PubMed  Google Scholar 

  67. Hatchuel DA, Peters E, Lemmer J, et al. Candidal infection in oral lichen planus. Oral Surg Oral Med Oral Pathol 1990;70:172–5.

    Article  CAS  PubMed  Google Scholar 

  68. Carbone M, Conrotto D, Carrozzo M, et al. Topical corticosteroids in association with miconazole and chlorhexidine in the long-term management of atrophic-erosive oral lichen planus: A placebo-controlled and comparative study between clobetasol and fluocinonide. Oral Dis 1999;5:44–9.

    Article  CAS  PubMed  Google Scholar 

  69. Zegarelli DJ. Treatment of oral lichen planus with topical vitamin A acid. J Oral Med 1984;39:186–91.

    CAS  PubMed  Google Scholar 

  70. Al Johani KA, Hegarty AM, Porter SR, et al. Calcineurin inhibitors in oral medicine. J Am Acad Dermatol 2009;61:829–40.

    Article  PubMed  CAS  Google Scholar 

  71. Conrotto D, Carbone M, Carrozzo M, et al. Ciclosporin vs. clobetasol in the topical management of atrophic and erosive oral lichen planus: A double-blind, randomized controlled trial. Br J Dermatol 2006;154:139–45.

    Article  CAS  PubMed  Google Scholar 

  72. Rozycki TW, Rogers RS 3rd, Pittelkow MR, et al. Topical tacrolimus in the treatment of symptomatic oral lichen planus: A series of 13 patients. J Am Acad Dermatol 2002;46:27–34.

    Article  PubMed  Google Scholar 

  73. Morrison L, Kratochvil FJ 3rd, Gorman A. An open trial of topical tacrolimus for erosive oral lichen planus. J Am Acad Dermatol 2002;47:617–20.

    Article  PubMed  Google Scholar 

  74. Becker JC, Houben R, Vetter CS, et al. The carcinogenic potential of tacrolimus ointment beyond immune suppression: A hypothesis creating case report. BMC Cancer 2006;6:7.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  75. Niwa Y, Terashima T, Sumi H. Topical application of the immunosuppressant tacrolimus accelerates carcinogenesis in mouse skin. Br J Dermatol 2003;149:960–7.

    Article  CAS  PubMed  Google Scholar 

  76. Woo TY. Systemic isotretinoin treatment of oral and cutaneous lichen planus. Cutis 1985;35:385–6, 390–1, 393.

    Google Scholar 

  77. Lear JT, English JS. Erosive and generalized lichen planus responsive to azathioprine. Clin Exp Dermatol 1996;21:56–7.

    Article  CAS  PubMed  Google Scholar 

  78. Hallopeau H. Sur un cas de lichen de Wilson gingival avec neoplasie voisine dans la region maxillaire. Bull Soc Fr Dermatol Syphiligr 1910;17:32.

    Google Scholar 

  79. Krutchkoff DJ, Cutler L, Laskowski S. Oral lichen planus: The evidence regarding potential malignant transformation. J Oral Pathol 1978;7:1–7.

    Article  CAS  PubMed  Google Scholar 

  80. Van der Meij EH, Schepman KP, van der Wal JE, et al. A review of the recent literature regarding malignant transformation of oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999;88:307–10.

    Article  PubMed  Google Scholar 

  81. Gonzalez-Moles MA, Scully C, Gil-Montoya JA. Oral lichen planus: Controversies surrounding malignant transformation. Oral Dis 2008;14:229–43.

    Article  CAS  PubMed  Google Scholar 

  82. Mattsson U, Jontell M, Holmstrup P. Oral lichen planus and malignant transformation: Is a recall of patients justified? Crit Rev Oral Biol Med 2002;13:390–6.

    Article  PubMed  Google Scholar 

  83. Gandolfo S, Richiardi L, Carrozzo M, et al. Risk of oral squamous cell carcinoma in 402 patients with oral lichen planus: A follow-up study in an Italian population. Oral Oncol 2004;40:77–83.

    Article  CAS  PubMed  Google Scholar 

  84. Zhang L, Cheng X, Li Y, et al. High frequency of allelic loss in dysplastic lichenoid lesions. Lab Invest 2000;80:233–7.

    Article  CAS  PubMed  Google Scholar 

  85. Kim J, Yook JI, Lee EH, et al. Evaluation of premalignant potential in oral lichen planus using interphase cytogenetics. J Oral Pathol Med 2001;30:65–72.

    Article  CAS  PubMed  Google Scholar 

  86. Krogh P, Holmstrup P, Thorn JJ, et al. Yeast species and biotypes associated with oral leukoplakia and lichen planus. Oral Surg Oral Med Oral Pathol 1987;63:48–54.

    Article  CAS  PubMed  Google Scholar 

  87. Cox M, Maitland N, Scully C. Human herpes simplex-1 and papillomavirus type 16 homologous DNA sequences in normal, potentially malignant and malignant oral mucosa. Eur J Cancer B Oral Oncol 1993;29B:215–19.

    Article  CAS  PubMed  Google Scholar 

  88. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999;397:530–4.

    Article  CAS  PubMed  Google Scholar 

  89. Barnard NA, Scully C, Eveson JW, et al. Oral cancer development in patients with oral lichen planus. J Oral Pathol Med 1993;22:421–4.

    Article  CAS  PubMed  Google Scholar 

  90. Sudbo J, Ried T, Bryne M, et al. Abnormal DNA content predicts the occurrence of carcinomas in non-dysplastic oral white patches. Oral Oncol 2001;37:558–65.

    Article  CAS  PubMed  Google Scholar 

  91. Zhang L, Michelsen C, Cheng X, et al. Molecular analysis of oral lichen planus. A premalignant lesion? Am J Pathol 1997;151:323–7.

    PubMed Central  CAS  PubMed  Google Scholar 

  92. Reichart PA, Philipsen HP. Oral erythroplakia—a review. Oral Oncol 2005;41:551–61.

    Article  PubMed  Google Scholar 

  93. Kramer IR, Lucas RB, Pindborg JJ, et al. Definition of leukoplakia and related lesions: An aid to studies on oral precancer. Oral Surg Oral Med Oral Pathol 1978;46:518–39.

    Article  CAS  PubMed  Google Scholar 

  94. Pindborg JJ, Reichart PA, Smith CJ, van der Waal I, in collaboaration with Sobin L.H. and pathologists in 9 countries editors. Histological typing of cancer and precancer of the oral mucosa. 2nd ed. Berlin, New York, Tokyo: Springer Verlag; 1997.

    Google Scholar 

  95. Shafer WG, Waldron CA. Erythroplakia of the oral cavity. Cancer 1975;36:1021–8.

    Article  CAS  PubMed  Google Scholar 

  96. Hashibe M, Mathew B, Kuruvilla B, et al. Chewing tobacco, alcohol, and the risk of erythroplakia. Cancer Epidemiol Biomarkers Prev 2000;9:639–45.

    CAS  PubMed  Google Scholar 

  97. Thomas G, Hashibe M, Jacob BJ, et al. Risk factors for multiple oral premalignant lesions. Int J Cancer 2003;107:285–91.

    Article  CAS  PubMed  Google Scholar 

  98. Jacob BJ, Straif K, Thomas G, et al. Betel quid without tobacco as a risk factor for oral precancers. Oral Oncol 2004;40:697–704.

    Article  PubMed  Google Scholar 

  99. Sudbo J, Kildal W, Johannessen AC, et al. Gross genomic aberrations in precancers: Clinical implications of a long-term follow-up study in oral erythroplakias. J Clin Oncol 2002;20:456–62.

    Article  PubMed  Google Scholar 

  100. Qin GZ, Park JY, Chen SY, et al. A high prevalence of p53 mutations in pre-malignant oral erythroplakia. Int J Cancer 1999;80:345–8.

    Article  CAS  PubMed  Google Scholar 

  101. Tilakaratne WM, Klinikowski MF, Saku T, et al. Oral submucous fibrosis: Review on aetiology and pathogenesis. Oral Oncol 2006;42:561–8.

    Article  CAS  PubMed  Google Scholar 

  102. Rajendran R, Vijayakumar T, Vasudevan DM. An alternative pathogenetic pathway for oral submucous fibrosis (OSMF). Med Hypotheses 1989;30:35–7.

    Article  CAS  PubMed  Google Scholar 

  103. Aziz SR. Coming to America: Betel nut and oral submucous fibrosis. J Am Dent Assoc 2010;141:423–8.

    Article  PubMed  Google Scholar 

  104. Maher R, Lee AJ, Warnakulasuriya KA, et al. Role of areca nut in the causation of oral submucous fibrosis: A case–control study in Pakistan. J Oral Pathol Med 1994;23:65–9.

    Google Scholar 

  105. Vilcek J, Palombella VJ, Henriksen-DeStefano D, et al. Fibroblast growth enhancing activity of tumor necrosis factor and its relationship to other polypeptide growth factors. J Exp Med 1986;163:632–43.

    Article  CAS  PubMed  Google Scholar 

  106. Liu CJ, Lee YJ, Chang KW, et al. Polymorphism of the MICA gene and risk for oral submucous fibrosis. J Oral Pathol Med 2004;33:1–6.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of General Surgery, 2D4.39 Walter Mackenzie Health Sciences Center, 8440-112 Street, Edmonton, AB, T6G 2B7, Canada

    David C. Williams

  2. Division of Oral Medicine and Pathology, University of Alberta, Room 5082, Dentistry-Pharmacy Building, Edmonton, AB, T6G 2NA, Canada

    William T. McGaw

Authors
  1. David C. Williams
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William T. McGaw
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David C. Williams .

Editor information

Editors and Affiliations

  1. Head and Neck Surgical Oncology, Cancer Care Manitoba, Winnipeg, Manitoba, Canada

    K. Alok Pathak

  2. Surgery, University of Manitoba, Winnipeg, Manitoba, Canada

    Richard W. Nason

Rights and permissions

Reprints and permissions

Copyright information

© 2012 The Author(s)

About this chapter

Cite this chapter

Williams, D.C., McGaw, W.T. (2012). Potentially Malignant Disorders of the Oral Cavity. In: Pathak, K., Nason, R. (eds) Controversies in Oral Cancer. Head and Neck Cancer Clinics. Springer, New Delhi. https://doi.org/10.1007/978-81-322-2574-4_2

Download citation

  • DOI: https://doi.org/10.1007/978-81-322-2574-4_2

  • Publisher Name: Springer, New Delhi

  • Print ISBN: 978-81-322-2573-7

  • Online ISBN: 978-81-322-2574-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation